PLX vs. CCCC, AVXL, SOPH, STRO, SLDB, MGTX, TNYA, BDTX, GNFT, and PSTX
Should you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include C4 Therapeutics (CCCC), Anavex Life Sciences (AVXL), SOPHiA GENETICS (SOPH), Sutro Biopharma (STRO), Solid Biosciences (SLDB), MeiraGTx (MGTX), Tenaya Therapeutics (TNYA), Black Diamond Therapeutics (BDTX), Genfit (GNFT), and Poseida Therapeutics (PSTX). These companies are all part of the "biological products, except diagnostic" industry.
C4 Therapeutics (NASDAQ:CCCC) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends.
C4 Therapeutics has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
C4 Therapeutics presently has a consensus target price of $10.13, suggesting a potential upside of 117.27%. Protalix BioTherapeutics has a consensus target price of $10.00, suggesting a potential upside of 777.96%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than C4 Therapeutics.
78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 8.0% of C4 Therapeutics shares are owned by insiders. Comparatively, 5.0% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Protalix BioTherapeutics has higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
C4 Therapeutics received 20 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 62.50% of users gave Protalix BioTherapeutics an outperform vote while only 37.88% of users gave C4 Therapeutics an outperform vote.
Protalix BioTherapeutics has a net margin of 11.48% compared to Protalix BioTherapeutics' net margin of -629.24%. C4 Therapeutics' return on equity of 19.48% beat Protalix BioTherapeutics' return on equity.
In the previous week, C4 Therapeutics had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for C4 Therapeutics and 0 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.77 beat C4 Therapeutics' score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the media.
Summary
Protalix BioTherapeutics beats C4 Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Protalix BioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protalix BioTherapeutics Competitors List
Related Companies and Tools
